S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
Log in

NASDAQ:JAGX - Jaguar Health Stock Price, Forecast & News

$0.57
-0.03 (-5.00 %)
(As of 02/28/2020 04:00 PM ET)
Today's Range
$0.54
Now: $0.57
$0.60
50-Day Range
$0.60
MA: $0.74
$0.96
52-Week Range
$0.52
Now: $0.57
$36.39
Volume303,298 shs
Average Volume640,709 shs
Market Capitalization$29.16 million
P/E RatioN/A
Dividend YieldN/A
Beta0.79
Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:JAGX
CUSIPN/A
Phone415-371-8300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.42 million
Book Value$5.80 per share

Profitability

Net Income$-32,150,000.00
Net Margins-771.25%

Miscellaneous

Employees40
Market Cap$29.16 million
Next Earnings Date4/8/2020 (Estimated)
OptionableNot Optionable

Receive JAGX News and Ratings via Email

Sign-up to receive the latest news and ratings for JAGX and its competitors with MarketBeat's FREE daily newsletter.


Jaguar Health (NASDAQ:JAGX) Frequently Asked Questions

What is Jaguar Health's stock symbol?

Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."

How were Jaguar Health's earnings last quarter?

Jaguar Health Inc (NASDAQ:JAGX) released its earnings results on Monday, November, 14th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.40) by $0.10. The biotechnology company had revenue of $0.05 million for the quarter, compared to analysts' expectations of $0.10 million. Jaguar Health had a negative net margin of 771.25% and a negative return on equity of 675.03%. View Jaguar Health's Earnings History.

When is Jaguar Health's next earnings date?

Jaguar Health is scheduled to release their next quarterly earnings announcement on Wednesday, April 8th 2020. View Earnings Estimates for Jaguar Health.

What price target have analysts set for JAGX?

2 equities research analysts have issued 12-month target prices for Jaguar Health's shares. Their forecasts range from $3.00 to $5.00. On average, they expect Jaguar Health's stock price to reach $4.00 in the next year. This suggests a possible upside of 601.8% from the stock's current price. View Analyst Price Targets for Jaguar Health.

What is the consensus analysts' recommendation for Jaguar Health?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jaguar Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Jaguar Health.

Has Jaguar Health been receiving favorable news coverage?

Press coverage about JAGX stock has trended somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Jaguar Health earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Jaguar Health.

Who are some of Jaguar Health's key competitors?

What other stocks do shareholders of Jaguar Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biopharmx (BPMX), Conatus Pharmaceuticals (CNAT), Cara Therapeutics (CARA), Precipio (PRPO), Neovasc (NVCN), PTC Therapeutics (PTCT), Biocept (BIOC), Cascadian Therapeutics (CASC), Cellectar Biosciences (CLRB) and SCYNEXIS (SCYX).

Who are Jaguar Health's key executives?

Jaguar Health's management team includes the folowing people:
  • Ms. Lisa A. Conte, Founder, CEO, Pres & Director (Age 60)
  • Ms. Karen S. Wright, CFO & Treasurer (Age 63)
  • Dr. Steven R. King, Exec. VP of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec. (Age 61)
  • Dr. Pravin R. Chaturvedi, Chair of Scientific Advisory Board & Acting Chief Scientific Officer (Age 56)
  • Mr. Jonathan S. Wolin, Chief Compliance Officer & Corp. Counsel

When did Jaguar Health IPO?

(JAGX) raised $22 million in an IPO on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

Who are Jaguar Health's major shareholders?

Jaguar Health's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.21%). Company insiders that own Jaguar Health stock include James J Bochnowski, Jonathan B Siegel, Lisa A Conte and Nantucket Investments Ltd. View Institutional Ownership Trends for Jaguar Health.

Which institutional investors are buying Jaguar Health stock?

JAGX stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Jaguar Health stock in the last two years include James J Bochnowski, Jonathan B Siegel and Lisa A Conte. View Insider Buying and Selling for Jaguar Health.

How do I buy shares of Jaguar Health?

Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Jaguar Health's stock price today?

One share of JAGX stock can currently be purchased for approximately $0.57.

How big of a company is Jaguar Health?

Jaguar Health has a market capitalization of $29.16 million and generates $4.42 million in revenue each year. The biotechnology company earns $-32,150,000.00 in net income (profit) each year or ($158.74) on an earnings per share basis. Jaguar Health employs 40 workers across the globe.View Additional Information About Jaguar Health.

What is Jaguar Health's official website?

The official website for Jaguar Health is http://www.jaguaranimalhealth.com/.

How can I contact Jaguar Health?

Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The biotechnology company can be reached via phone at 415-371-8300.


MarketBeat Community Rating for Jaguar Health (NASDAQ JAGX)

Community Ranking:  4.4 out of 5 (star star star star)
Outperform Votes:  1,805 (Vote Outperform)
Underperform Votes:  247 (Vote Underperform)
Total Votes:  2,052
MarketBeat's community ratings are surveys of what our community members think about Jaguar Health and other stocks. Vote "Outperform" if you believe JAGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel